Screening for endogenous hypercortisolism in patients with osteoporosis and fractures: why, when and how

• Published in: Journal of endocrinological investigation
• Main Authors: Giordano, Roberta, Parasiliti Caprino, Mirko, Loli, Paola, Giustina, Andrea
• Format: Journal Article
• Language: English
• Published: Italy 03-10-2024
• Subjects: Osteoporosis; Screening; Vertebral fractures; Glucocorticoids; Vertebral morphometry; Bone mineral density; Cushing’s syndrome
• ISSN: 1720-8386; 1720-8386
• DOI: 10.1007/s40618-024-02450-y

Skeletal comorbidities are frequent and clinically relevant findings in Cushing's syndrome (CS) since an uncoupled suppressed bone formation and enhanced bone resorption leads to a marked skeletal damage with a rapid increase of fracture risk. Reduced Bone Mineral Density (BMD) has been consistently reported and osteopenia or osteoporosis are typical findings in patients with CS. Vertebral Fractures (VFs) are frequently reported and may occur even in patients with an only mild reduction of BMD. Since CS is diagnosed late due to often difficult biochemical and radiological confirmation as well as to signs and symptoms common in other much more frequent diseases an approach suggested for overcoming underdiagnosis is to screen patients with manifestations which may overlap with those of CS such as arterial hypertension, diabetes mellitus and osteoporosis. Our review will focus on the rationale and best practice for screening osteoporotic patients for CS.